ClinicalTrials.gg
CompletedNCT04484779Updated Jan 7, 2021

A Study of an Insulin Management System in Participants With Type 1 or Type 2 Diabetes

An interventional study of IIM System and Insulin Lispro and/or Insulin Glargine in Type 1 Diabetes and Type 2 Diabetes, sponsored by Eli Lilly and Company. Completed at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-01-07.

Sponsored by Eli Lilly and Company · Not applicable, Interventional, and Device feasibility

From the registry’s dates

  • Primary completion was Dec 2020, 5 years 10 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
67
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 69 studies testing Insulin Lispro in Diabetes Mellitus, Type 1 — 3 open to participants now, 3 under way, none of them phase 3. Insulin Lispro · Diabetes Mellitus, Type 1.

Enrollment
26th of 69
67 · median 38
Started
2020
with 3 others
No phase
13 of 69
2 open now
Registered
60th of 69
by date
Lead sponsor
31 of 69
Eli Lilly and Company

Among the 69 studies testing Insulin Lispro in Diabetes Mellitus, Type 1, this one is the 26th largest by enrollment, is one of 4 that started in 2020, is one of 13 with no phase, and was the 60th registered.

Diabetes Mellitus, Type 1

3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

3 of the 69 studies testing Insulin Lispro in Diabetes Mellitus, Type 1 are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About Insulin Lispro

Insulin Lispro: first FDA approval 1996 (HUMALOG KWIKPEN), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 414 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 260 (63%) stop at 75 or younger; 187 take children under 18; 64 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies testing Insulin Lispro in Diabetes Mellitus, Type 1, or all of them as a file.
02

Study summary

The purpose of this study is to investigate the user experience of an integrated insulin management system (IIM) in participants with type 1 or type 2 diabetes. The IIM system is comprised of an insulin injection pen with a data transmission module and blood glucose meter which are connected to a mobile phone application. The application will be used to record and track diabetes-data related information.

03

Conditions studied

  • Type 1 Diabetes
  • Type 2 Diabetes
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed (clinically) with type 1 diabetes (T1D) for at least 1 year or type 2 diabetes (T2D) for at least 6 months.
  • Using insulin injection regimen of basal/bolus or basal only for 3 months prior to screening, which includes:

    • for bolus insulin (U-100) - a rapid-acting insulin analog (glulisine, lispro, or aspart).
    • for basal insulin - degludec (U-100 or U-200), detemir (U-100), or glargine (U- 100 or U-300).
  • Participants with T2D may be on ≤ 3 anti-hyperglycemic medications in addition to insulin, including alpha-glucosidase inhibitors, dipeptidyl peptidase 4 (DPP-4) inhibitors, glucagon-like peptide 1 receptor agonist (GLP-1 RA; oral or injectable), meglitinides, metformin, sodium-glucose cotransporter-2 inhibitors (SGLTi-2), sulfonylureas, or thiazolidinediones consistent with product labeling.
  • Participants with T1D must be on insulin only.
  • Have point-of-care (HbA1c) value of ≤11% at screening.
  • Must be able to self-inject insulin dose (basal or basal/bolus) without assistance.
  • If using Continuous Glucose Monitoring or Flash Glucose Monitoring device, must agree to stop use throughout duration of trial.
  • Must be able to read and speak English.
  • Able and willing to use only study-provided insulin Basaglar and/or Humalog for duration of trial.
  • Able and willing to follow insulin regimen specified by investigator throughout duration of trial, insulin dose may be titrated at investigator's discretion.
  • Have no physical or cognitive disabilities that would, in the opinion of the investigator, preclude participant from using sponsor-provided iOS device for study activities and comply with study requirements.
  • Agree not to post any personal medical data, pictures of the IIM system or information related to the study on any website or social media site (for example, Facebook, Twitter, LinkedIn, etc.).
  • Have refrigeration in home for storage of insulin.
  • Women of participating:

    • Cannot be pregnant or intend to become pregnant during the trial period
    • Cannot be breastfeeding (including the use of a breast pump)
    • Must remain abstinent or
    • Must use 1 highly effective method (less than 1% failure rate) of or a combination of 2 effective methods of contraception for the entirety of the study and
    • Test negative for pregnancy based on a urine pregnancy test at the time of screening. Additional local urine pregnancy tests may be conducted for duration of trial at discretion of investigator.

Exclusion criteria

Exclusion Criteria:

  • If not able to take the basal insulin dose in 1 injection per day.
  • Have experienced an episode of severe hypoglycemia (defined as requiring assistance due to neurologically disabling hypoglycemia) within 3 months prior to screening.
  • Have hypoglycemia unawareness as judged by the investigator.
  • Have had 1 or more emergency room visits or hospitalization due to poor glucose control (hyperglycemia or diabetic ketoacidosis [DKA]) within 3 months prior to screening.
  • History of renal transplantation, receiving renal dialysis, or diagnosed with stage IV chronic kidney disease.
  • Any of the following cardiovascular conditions within 6 months prior to screening: i. acute myocardial infarction (MI) ii. cerebrovascular accident (stroke) iii. unstable angina, or iv. hospitalization due to congestive heart failure (CHF)
  • Presence or history of severe congestive heart failure ( Class IV [CCNYHA 1994]).
  • Have history of or clinical signs of liver disease (for example, acute or chronic hepatitis, or cirrhosis).
  • Have active or untreated except basal cell or squamous cell skin cancer.
  • Have any or allergy to any of the insulins or used in this trial.
  • Have vision loss or vision impairment that does not allow recognition of MMA screen features.
  • Have impaired dexterity which limits ability to use injection device or mobile MMA.
  • Are currently enrolled in any other clinical study involving an product or any other type of medical research judged not to be scientifically or medically compatible with this study.
  • Have participated, within the last 30 days, in a clinical study involving an investigational product. If the previous investigational product has a long halflife, 5 half-lives or 30 days (whichever is longer) should have passed.
  • Have previously completed or withdrawn from this study.
  • Have previously used or are currently using an approved or investigational connected pen system.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Device feasibility
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
67 participants (actual)

Study arms

  • Experimental
    IIM System

    The IIM system is comprised of an insulin lispro pen and/or an insulin glargine pen (both U-100), an investigational mobile medical application (MMA) that transmits data to cloud storage, an investigational Bluetooth Low Energy® (BLE)-paired insulin data transmission (IDT) module and a compatible commercially available BLE-paired blood glucose meter (BGM).

    Device: IIM System · Drug: Insulin Lispro and/or Insulin Glargine

Interventions

06

What researchers measure

Primary outcomes

  1. Total and Domain Specific Score of the mHealth App Usability Questionnaire (MAUQ) for Standalone mHealth Apps Used by Patients

    Total and Domain Specific Score of the MAUQ for Standalone mHealth Apps Used by Patients

    Time frame: 10 Weeks

Secondary outcomes

  1. Overall Ease of Use of the IIM System

    Overall Ease of Use of the IIM System Assessed by the Participant Feedback Form

    Time frame: 10 Weeks

  2. Likelihood of Site to Recommend the IIM System

    Likelihood of Site to Recommend the IIM System Assessed by the Site Feedback Form

    Time frame: 10 Weeks

07

Study locations

5 sites
  • Medical Investigations Inc.
    Little Rock, Arkansas 72211, United States
  • Diablo Clinical Research, Inc.
    Walnut Creek, California 94598, United States
  • Texas Diabetes & Endocrinology, P.A.
    Austin, Texas 78731-4309, United States
  • Texas Diabetes & Endocrinology, P.A.
    Round Rock, Texas 78681, United States
  • Rainier Clinical Research Center
    Renton, Washington 98057, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2020 to primary completion in Dec 2020, 5 months.

Of 105 industry-sponsored interventional studies with no phase under Diabetes Mellitus, Type 1, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 18. This study's 5 months is below that.

Counting every sponsor, half of 952 studies reached it within 18 months; a quarter within 9 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 10, 2020
First posted
Jul 24, 2020
StartActual
Jul 14, 2020
Primary completionActual
Dec 22, 2020
CompletionActual
Dec 22, 2020
Last update
Jan 7, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 7, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04484779
Responsible party
Sponsor
First posted
Jul 24, 2020
Start date
Jul 14, 2020
Primary completion
Dec 22, 2020
Completion
Dec 22, 2020
Last update
Jan 7, 2021

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-532-0186 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Insulin Lispro · Insulin Glargine

Start the discussion